Barclays Maintains Overweight on Protagonist Therapeutics, Raises Price Target to $151

Benzinga Newsdesk www.benzinga.com Positive 85.1%

Neg 0% Neu 0% Pos 85.1%

Barclays analyst Etzer Darout maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Overweight and raises the price target from $119 to $151.